Tag Archives: AML

February, 2017

January, 2017

December, 2016

November, 2016

  • 14 November

    Novartis’ Leukemia Drug Wins Priority Review from the FDA

    Basel, November 14, 2016 – Novartis today announced that the US Food and Drug Administration (FDA) granted Priority Review to the PKC412 (midostaurin) new drug application (NDA) for the treatment of acute myeloid leukemia (AML) in newly-diagnosed adults with an FMS-like tyrosine kinase-3 (FLT3) mutation, as well as for the …

October, 2016

August, 2016